A primer on the epigenetics of kidney fibrosis.
Despite extensive knowledge of the various molecular pathways that contribute to tubulointerstitial fibrosis, it remains an unsolved question why the progression rate of chronic kidney disease varies substantially from patient to patient, even among patients with common underlying nephropathies and comorbidities. Possible explanations for different susceptibilities of individual patients to develop end-stage renal failure include genetic or epigenetic variations, which modify how individual patients respond to kidney injury. Here we review principles of epigenetic mechanisms in context of chronic kidney disease and discuss how such insights may be utilized for future therapeutic strategies and may lead to novel diagnostic tools in the future.
Department of Nephrology and Rheumatology, Göttingen University Medical Center, Georg August University, Göttingen, Germany.
D
D
Tampe
M
M
Zeisberg
D001284:Atrophy / Q000235:genetics; D002908:Chronic Disease; D019175:DNA Methylation / Q000235:genetics; D018450:Disease Progression; D044127:Epigenesis, Genetic; D005347:Fibroblasts / Q000502:physiology; D005355:Fibrosis; D005819:Genetic Markers; D006657:Histones / Q000502:physiology; D006801:Humans; D007668:Kidney / Q000473:pathology*; D007674:Kidney Diseases / Q000235:genetics* / Q000473:pathology; D007684:Kidney Tubules / Q000473:pathology; D009395:Nephritis, Interstitial / Q000235:genetics
D005819:Genetic Markers; D006657:Histones